Cemacabtagene ansegedleucel (cema-cel, formerly ALLO-501A) is being evaluated in the Phase II ALPHA3 trial in patients who respond to first-line chemoimmunotherapy but remain positive for minimal residual <a href="https://healthylife7.com/new-25-million-accelerator-bets-on-better-model-for-rare-disease/” title=”New $25 Million Accelerator Bets On Better Model For Rare Disease”>disease. At day 45, plasma circulating tumour DNA had decreased by a median of 97.7 per cent with cema-cel, versus a 26.6 per cent increase under observation. No cytokine release syndrome, neurotoxicity, graft-versus-host disease or treatment-related serious adverse events were reported at the interim cut-off.
Cema-cel is edited with TALEN rather than CRISPR-Cas. Pairs of TALEN proteins recognise selected DNA sequences and bring together FokI nuclease domains, which cut the intervening DNA. Error-prone repair then disrupts TRAC, removing the donor cells’ native T-cell receptor to reduce graft-versus-host disease, and CD52, originally intended to protect the cells during anti-CD52 lymphodepletion. A lentiviral vector separately introduces the CD19-directed CAR
The analysis remains small and interim; MRD clearance has not yet demonstrated improved event-free survival. RMAT and Fast Track designations facilitate regulatory interaction but do not constitute approval
The news was revealed in a press release issued by Allogene Therapeutics on 29 July 2026. The TALEN construction was published in Molecular Therapy on 14 December 2022
To get more CRISPR Medicine News delivered to your inbox, sign up to the free weekly CMN Newsletter here
ArticleCMN BriefsNewsClinical News UpdatesCMN BriefsB-cell Malignancy, NHLCancerCAR-TAllogene Therapeutics, Inc.Clinical
